image: Led by Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, and Petrina Kamya, PhD, Global Head of AI Platforms, Insilico’s experienced team will participate in the conference.
Credit: Insilico Medicine
Insilico Medicine (“Insilico”), a clinical-stage, generative AI-driven drug discovery company, today announced its participation in NeurIPS 2025, to be held in San Diego, USA, from December 2–7, 2025. Led by Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, and Petrina Kamya, PhD, Global Head of AI Platforms, Insilico’s experienced team will participate in the conference.
Dr. Alex Zhavoronkov will participate in the NeurIPS 2025 Workshop “AI Virtual Cells and Instruments: A New Era in Drug Discovery and Development”, taking place at the San Diego Convention Center on Saturday, December 6, 2025.
As a leading interdisciplinary conference uniting thousands of researchers across machine learning, neuroscience, statistics, optimization, computer vision, natural language processing, and the life and social sciences, NeurIPS provides a premier platform for cutting-edge AI innovation and scientific collaboration. Insilico is honored to participate and showcase its pharma superintelligence and other latest generative AI breakthroughs that are revolutionizing drug discovery and development. Through workshop sessions, Insilico's expert team will demonstrate how generative AI is accelerating therapeutic discovery, improving drug efficacy, and advancing personalized medicine across multiple therapeutic areas.
"NeurIPS is an exceptionally important conference in AI, and Insilico Medicine has been a proud participant for years," said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. “This year, together with Dr. Petrina Kamya, we are introducing our innovative AI for Science Superintelligence concept—a transformative and disruptive platform that we will be launching next year. Conceived last year, this idea has been thoroughly developed and refined over the past twelve months by our dedicated AI and CADD teams. By integrating advanced machine learning, deep learning, and generative AI technologies, this platform aims to tackle some of the most challenging problems in modern science and medicine. It is a true honor to attend NeurIPS and connect with leading AI experts, researchers, and industry pioneers from around the world. These interactions not only spark new ideas but also create invaluable opportunities for cross-disciplinary collaboration and innovation in the industry. During our workshop sessions, we will provide an exclusive preview of this novel concept, which covers critical domains including computational biology, medicinal chemistry, clinical research, and longevity science. We believe this platform will significantly accelerate the drug discovery process and optimize therapeutic development.
After first describing the concept of using generative AI for the design of novel molecules in a peer-reviewed journal in 2016, Insilico has proceeded to the exploration into “Pharmaceutical Superintelligence”, aspiring for a future where AI platforms enable autonomous drug discovery without relying on human guidance. To dive deeper into the innovative concept, please refer to two recent preprint papers focusing on TargetPro and Target Benchmark, Insilico’s biology superintelligence system for de-risking and pipeline prioritization, and LEGION, a powerful AI-driven workflow for systematic chemical space exploration.
Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D.While traditional early-stage drug discovery typically requires 2.5 to 4 years, Insilico has nominated 20 preclinical candidates with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.
Since founding in 2014, Insilico has published over 200 peer-reviewed papers. Leveraging sustained scientific breakthroughs at the intersection of biotechnology, artificial intelligence, and automation, Insilico ranked Top 100 global corporate institutions in Nature Index's "2025 Research Leaders: global corporate institutions for biological sciences and natural sciences publications".
About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, visit www.insilico.com.